Basics ADMA Biologics Inc ADMA Biologics Inc is a biopharmaceutical company. The company develops and manufactures specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases. IPO Date: October 18, 2013 Sector: Healthcare Industry: Biotech Market Cap: $4.29B Activated in VL: True Average Daily Range Avg Daily Range: $0.15 | 2.78% Avg Daily Range (30 D): $0.35 | 1.85% Avg Daily Range (90 D): $0.45 | 2.30% Institutional Daily Volume Avg Daily Volume: 1.57M Avg Daily Volume (30 D): 2.5M Avg Daily Volume (90 D): 2.79M Trade Size Avg Trade Size (Sh.): 193 Avg Trade Size (Sh.) (30 D): 80 Avg Trade Size (Sh.) (90 D): 81 Institutional Trades Total Inst.Trades: 1,692 Avg Inst. Trade: $3.39M Avg Inst. Trade (30 D): $5.6M Avg Inst. Trade (90 D): $4.47M Avg Inst. Trade Volume: .33M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $5.22M Avg Closing Trade (30 D): $10.77M Avg Closing Trade (90 D): $9.75M Avg Closing Volume: 508.19K     News May 6, 2025 @ 8:11 PM 3 Mid-Cap Medical Stocks Outperforming the Market Source: Marketbeat.Com Apr 7, 2025 @ 11:00 AM ADMA Biologics Statement on Tariffs Source: N/A Mar 4, 2025 @ 6:50 PM BREAKING: Block & Leviton Investigating ADMA Biolo... Source: Block & Leviton Nov 2, 2024 @ 10:18 AM BFA Law is Investigating ADMA BIOLOGICS for Securi... Source: N/A Oct 27, 2024 @ 12:06 PM ADMA FRAUD ALERT: BFA Law Notifies ADMA Biologics ... Source: N/A Financials   TTM Q4 2024 FY 2024 Basic EPS $.11 $.48 $.85 Diluted EPS $.11 $.46 $.81 Revenue $ 114.8M $ 117.55M $ 426.45M Gross Profit $ 61.1M $ 63.33M $ 219.55M Net Income / Loss $ 26.9M $ 111.9M $ 197.67M Operating Income / Loss $ 34.88M $ 38.32M $ 138.98M Cost of Revenue $ 53.71M $ 54.22M $ 206.9M Net Cash Flow $ -31.52M $ 16.44M $ 51.8M PE Ratio 0.00